One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Preventing all-cause hospitalizations in type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A narrative review and proposed clinical approach
Meir Schechter MD, Matan Fischer MD, Ofri Mosenzon MD
doi : 10.1111/dom.14675
Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology
Simke W. Waijer MSc, Michele Provenzano PhD, Skander Mulder PhD, Peter Rossing MD, Frederik Persson MD, Vlado Perkovic MD, Hiddo J. L. Heerspink PhD
doi : 10.1111/dom.14660
Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC)
Bin Gao PhD, Weiguo Gao MSc, Hailong Wan MSc, Fengmei Xu MSc, Rong Zhou PhD, Xia Zhang MSc, Qiuhe Ji PhD
doi : 10.1111/dom.14661
Changes in pedometer-measured physical activity are associated with weight loss and changes in body composition and fat distribution in response to reduced-energy diet interventions: The POUNDS Lost trial
Qiaochu Xue MPH, Xiang Li MD, Hao Ma PhD, Zhou Tao PhD, Yoriko Heianza RD, Jennifer C. Rood PhD, George A Bray MD, Frank M Sacks MD, Lu Qi MD
doi : 10.1111/dom.14662
Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms
M. Ghidewon BA, H.S. Wald PhD, A. D. McKnight BS, B. C. De Jonghe PhD, D. M. Breen PhD, A. L. Alhadeff PhD, T. Borner PhD, H. J. Grill PhD
doi : 10.1111/dom.14663
Pramlintide for post-bariatric hypoglycaemia
Amanda Sheehan NP, Allison Goldfine MD, Muhammed Bajwa MD, Danielle Wolfs MPH, Chisayo Kozuka PhD, Jacqueline Piper BSN, Kristen Fowler NP, Mary Elizabeth Patti MD
doi : 10.1111/dom.14665
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: A meta-analysis and meta-regression analysis
Satoshi Yoshiji MD, Hiroto Minamino MD, Daisuke Tanaka MD, PhD, Shunsuke Yamane MD, PhD, Norio Harada MD, PhD, Nobuya Inagaki MD, PhD
doi : 10.1111/dom.14666
The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs
Nikolaos Kotsopoulos PhD, Mark P. Connolly PhD, Michael Willis PhD, Andreas Nilsson MSc, Ã…sa Ericsson MSc, James Baker-Knight BSc
doi : 10.1111/dom.14667
Effect of mitochondrial-targeted antioxidants on glycaemic control, cardiovascular health, and oxidative stress in humans: A systematic review and meta-analysis of randomized controlled trials
Shaun Andrew Mason PhD, Glenn David Wadley PhD, Michelle Anne Keske PhD, Lewan Parker PhD
doi : 10.1111/dom.14669
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
Sabine Kahl MD, Anne Pernille Ofstad MD, PhD, Bernard Zinman MD, Christoph Wanner MD, Elke Schüler Dipl. Math., Naveed Sattar MD, Silvio E. Inzucchi MD, Michael Roden MD
doi : 10.1111/dom.14670
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial
Jennifer Y. Barraclough PhD, Jie Yu PhD, Gemma A. Figtree DPhil, Vlado Perkovic PhD, Hiddo J. L. Heerspink PhD, Brendon L. Neuen MBBS (Hons), Christopher P. Cannon MD, Kenneth W. Mahaffey MD, Aletta E. Schutte PhD, Bruce Neal PhD, Clare Arnott PhD
doi : 10.1111/dom.14671
Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials
Carl Spana, Robert Jordan, Steven Fischkoff
doi : 10.1111/dom.14672
Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
Weimin Wang MD, Xiang Song MD, Ying Lou PhD, Liying Du MSc, Dalong Zhu MD, Zhiguang Zhou MD
doi : 10.1111/dom.14674
Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double-blind, and placebo-controlled study
Minyoung Lee MD, Woo-je Lee MD, Jae Hyeon Kim MD, Byung-Wan Lee MD
doi : 10.1111/dom.14679
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV
David Z. I. Cherney MD, Francesco Cosentino MD, Richard E. Pratley MD, Samuel Dagogo-Jack MD, Robert Frederich MD, Mario Maldonado MD, Jie Liu MD, Annpey Pong PhD, Chih-Chin Liu PhD, Christopher P. Cannon MD, VERTIS CV Investigators
doi : 10.1111/dom.14677
Acute changes in plasma glucose increases left ventricular systolic function in insulin-treated patients with type 2 diabetes and controls
Andreas Andersen PhD, Peter G. Jørgensen PhD, Jonatan I. Bagger PhD, Maria P. A. Baldassarre PhD, Mikkel B. Christensen PhD, Ulrik Pedersen-Bjergaard DMSci, Tommi B. Lindhardt PhD, Gunnar Gislason PhD, Filip K. Knop PhD, Tina Vilsbøll DMSci
doi : 10.1111/dom.14682
Serum bile acid response to oral glucose is attenuated in patients with early type 2 diabetes and correlates with 2-hour plasma glucose in individuals without diabetes
Xuyi Wang PhD, Chang Chen PhD, Cong Xie PhD, Weikun Huang MSc, Richard L. Young PhD, Karen L. Jones PhD, Michael Horowitz PhD, Christopher K. Rayner PhD, Zilin Sun PhD, Tongzhi Wu PhD
doi : 10.1111/dom.14683
Feasibility study of a prototype extended-wear insulin infusion set in adults with type 1 diabetes
Jasmin R. Kastner, Nisha Venkatesh, Katie Brown, Douglas B. Muchmore, Elif Ekinci, Spiros Fourlanos, Jeffrey I Joseph, Miami Shafeeq, Leon Shi, Poul Strange, Paul J. Strasma, David N. O'Neal
doi : 10.1111/dom.14685
Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance
J. David Spence MD, Catherine Viscoli PhD, Walter N. Kernan MD, Lawrence H. Young MD, Karen Furie MD, Ralph DeFronzo MD, Muhammad Abdul-Ghani MD, Paresh Dandona MD, DPhil, Silvio E. Inzucchi MD
doi : 10.1111/dom.14687
Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes
Ele Ferrannini MD, Elisabeth Niemoeller MD, Terry Dex PharmD, Soraly Servera MD, Andrea Mari PhD
doi : 10.1111/dom.14688
Type 2 diabetes pharmacotherapy trends in high-risk subgroups
Jay Bae PhD, Dongju Liu MSc, Chanadda Chinthammit PhD, Zbigniew Kadziola MSc, Kristina Boye PhD, Kieren Mather MD
doi : 10.1111/dom.14678
Morning versus afternoon physical activity and health-related outcomes in individuals with type 2 diabetes
Megan Hetherington-Rauth PhD, João P. Magalhães PhD, Gil B. Rosa MSc, Inês R. Correia MSc, Tomás Carneiro BSc, Estela C. Oliveira BSc, LuÃs B. Sardinha PhD
doi : 10.1111/dom.14676
Risk of new-onset type 2 diabetes in 600 055 people after COVID-19: A cohort study
Morgan Birabaharan MD, David C. Kaelber MD, Jeremy H. Pettus MD, Davey M. Smith MD
doi : 10.1111/dom.14659
Indirect treatment comparisons: Choosing the right tool for the job
Richard E. Pratley MD, Anders Gorst-Rasmussen PhD
doi : 10.1111/dom.14664
Measurement of plasma glucagon in humans: A shift in the performance of a current commercially available radioimmunoassay kit
Tongzhi Wu PhD, Christopher K. Rayner PhD, Karen L. Jones PhD, Michael Horowitz PhD, Christine Feinle-Bisset PhD, Scott D. Standfield BSc, Cong Xie PhD, Carolyn F. Deacon PhD, Jens J. Holst PhD, Nicolai J. Wewer Albrechtsen PhD
doi : 10.1111/dom.14673
